Study objective: In US emergency departments (EDs), patients with low back pain are often treated with nonsteroidal anti-inflammatory drugs and muscle relaxants. We compare functional outcomes among patients randomized to a 1-week course of naproxenþplacebo versus naproxenþorphenadrine or naproxenþmethocarbamol.
INTRODUCTION Background
Low back pain causes 2.4% of visits to US emergency departments (EDs), resulting in 2.6 million visits annually. 1 In general, outcomes for these patients are unfavorable. One week after ED discharge, 70% of patients report persistent back-pain-related functional impairment and 69% report analgesic use within the previous 24 hours. 2 Among the subset of ED patients who present with acute, new-onset low back pain, outcomes are generally better; most will recover, although 10% to 20% of this group reports moderate or severe low back pain 3 months later and 30% report persistent low back pain-related functional impairment.
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Importance
It is not clear which medications should be prescribed for acute low back pain. Nonsteroidal anti-inflammatory drugs are more efficacious than placebo in regard to low back pain relief, global improvement, and requirement of analgesic medication 5 but are insufficient treatment for as many as half of all ED patients with low back pain, who continue to experience discomfort after ED discharge despite use of nonsteroidal anti-inflammatory drugs.
Editor's Capsule Summary
What is already known on this topic Muscle relaxants are sometimes prescribed for acute low back pain.
What question this study addressed
When added to nonsteroidal anti-inflammatory drugs, do muscle relaxants improve functional outcomes for acute low back pain?
What this study adds to our knowledge In this well-powered, 3-arm, controlled trial of 240 adults, outcomes were similar at 7 days regardless of whether patients received a nonsteroidal antiinflammatory drug with placebo, orphenadrine, or methocarbamol.
How this is relevant to clinical practice
On average, supplementing nonsteroidal antiinflammatory drugs with orphenadrine or methocarbamol does not improve functional outcomes in patients with acute low back pain.
Treatment of low back pain with multiple concurrent medications is common in the ED; emergency physicians often prescribe skeletal muscle relaxants or opioids in combination with nonsteroidal anti-inflammatory drugs. 1 However, combining oxycodone and acetaminophen, diazepam, or cyclobenzaprine (a skeletal muscle relaxant) with a nonsteroidal anti-inflammatory drug does not improve outcomes. 3 It remains uncertain whether adding other skeletal muscle relaxants to nonsteroidal antiinflammatory drugs improves low back pain outcomes.
Two specific skeletal muscle relaxants, orphenadrine and methocarbamol, are used in more than 250,000 US ED visits for low back pain annually, although scant evidence exists to determine the appropriateness of this approach. 6 Orphenadrine is a centrally acting medication with prominent anticholinergic and antihistaminic properties. The mechanism of action is not understood. Efficacy in low back pain may be related to nonspecific analgesic properties. The mechanism of action of methocarbamol has also not been established. Its efficacy is thought to be related to central nervous system effects rather than direct effects on skeletal muscles.
Goals of This Investigation
Given the poor pain and functional outcomes that persist beyond an ED visit for acute low back pain, we conducted a clinical trial to determine whether combining either orphenadrine or methocarbamol with a nonsteroidal anti-inflammatory drug is more effective than nonsteroidal anti-inflammatory drug monotherapy for the treatment of acute, nontraumatic, nonradicular low back pain. We specifically evaluated the following 2 hypotheses: that the combination of naproxenþorphenadrine provides greater relief of low back pain than naproxenþplacebo 1 week and 3 months after an ED visit, as measured by the RolandMorris Disability Questionnaire (RMDQ); and that the combination of naproxenþmethocarbamol provides greater relief of low back pain than naproxenþplacebo 1 week and 3 months after an ED visit, as measured by the RMDQ.
MATERIALS AND METHODS Study Design and Setting
This was a randomized, double-blind, comparative effectiveness study, in which we enrolled ED patients with musculoskeletal low back pain at discharge and followed them by telephone 7 days and 3 months later. Every patient received standard-of-care therapy, consisting of naproxen and a brief low back pain educational session. Patients were then randomized to orphenadrine, methocarbamol, or placebo. The Albert Einstein College of Medicine Institutional Review Board reviewed and approved this study. Written consent to participate was obtained for all study participants. Enrollment commenced in March 2016 and continued for 11 months. We report this trial in accordance with Consolidated Standards of Reporting Trials standards.
This study was performed in the 2 academic EDs of Montefiore Medical Center (Bronx, NY), with a combined annual census of 180,000 adult visits. Salaried, full-time, bilingual (English and Spanish), technician-level research associates staffed the EDs 18 to 24 hours per day, 7 days per week during the study period.
Selection of Participants
Our goal was to include a broad representation of patients with musculoskeletal back pain who would potentially respond to the investigational medications. The presence or absence of palpable spasm of the paraspinal muscles was not used as an entry criterion because the clinical significance and reliability of this finding are uncertain. 7 Patients were included if they were aged 18 years and no older than 69 years and presented to one of the participating EDs primarily for management of low back pain, defined as pain originating between the lower border of the scapulae and the upper gluteal folds. At the conclusion of the ED visit, the patient was required to have received a diagnosis consistent with nontraumatic, nonradicular, musculoskeletal low back pain and was to be discharged home. To participate, patients were required to have a baseline score of greater than 5 on the RMDQ (Appendix E1, available online at http://www. annemergmed.com). Patients were excluded from participation if they reported radicular pain below the gluteal folds, pain duration greater than 2 weeks, a baseline back pain frequency of at least once per month or substantial direct trauma to the back within the previous month. Patients were also excluded from participation if they would not be available for follow-up; for pregnancy or breast feeding; for a chronic pain syndrome defined as use of any analgesic medication daily or near daily; or for allergy, intolerance, or contraindication to the investigational medications.
Interventions
Study participants were randomized in a 1:1:1 ratio to orphenadrine, methocarbamol, or placebo. Participants in the orphenadrine arm were instructed to use naproxen 500-mg tablets twice per dayþorphenadrine 100 mg twice per day. Participants in the methocarbamol arm were instructed to use naproxen 500-mg tablets twice per dayþmethocarbamol 750 mg as 1 or 2 tablets 3 times per day; thus, they could receive as much as 1,500 mg of methocarbamol 3 times per day. Patients randomized to placebo were randomly assigned to 2 different sets of dosing instructions to match the different dosing regimens of the active arms; half of the participants were instructed to use the investigational capsule twice per day, whereas the other half were instructed to use it as 1 or 2 capsules 3 times per day.
We incorporated a flexible dosing plan in the methocarbamol arm in an effort to maximize effectiveness while minimizing adverse effects. In this study arm, patients were instructed to use 1 or 2 pills of the methocarbamol every 8 hours. If one tablet of the methocarbamol afforded sufficient relief, there was no need for the patient to use the second tablet. However, if the patient had not experienced sufficient relief within 30 minutes of using one investigational medication tablet, he or she was instructed to use the second tablet. We chose this method of administration because optimal dosing of methocarbamol has not been established. We believe the dosing regimen we chose was sufficient to determine effectiveness while not exposing patients to unnecessary risk. [8] [9] [10] Orphenadrine is manufactured in only 100-mg extended-release tablets and therefore was not amenable to flexible dosing. All study patients were given 14 naproxen tablets, a 7-day supply, and a sufficient number of investigational tablets to last 7 days.
The research pharmacist performed randomization in blocks of 6 based on a sequence generated at http:// randomization.com. Each block of 6 contained 2 orphenadrine assignments, 2 methocarbamol assignments, 1 placebo assignment dosed as 1 capsule twice daily (to mirror orphenadrine dosing), and 1 placebo assignment dosed as 1 to 2 capsules 3 times daily (to mirror methocarbamol dosing). Therefore, although patients did not know whether they had been assigned to active medication or placebo, they may have deduced to which medication they were not assigned. This did not threaten the internal validity of the study because patients did not know whether they received active medication or placebo.
Naproxen was not masked. Orphenadrine, methocarbamol, and placebo were masked by placing tablets into identical capsules, which were packed with scant amounts of lactose and sealed. This masking occurred in a secure location inaccessible to ED personnel. Study participants were presented with 2 bottles of medication. The first bottle, containing the naproxen, was labeled in a typical manner. The second bottle, containing orphenadrine, methocarbamol, or placebo, was labeled as investigational medication. Patients were instructed to use the second bottle of investigational medication only as needed for moderate or severe low back pain.
Research personnel provided each patient with a 10-minute educational intervention. This was based on the National Institute for Arthritis and Musculoskeletal Disease's Handout on Health: Back Pain information Web page (available at http://www.niams.nih.gov/Health_Info/ Back_Pain/default.asp). Research personnel reviewed each section of the information sheet with the patient and elicited questions.
Methods of Measurement
The RMDQ (Appendix E1, available online at http:// www.annemergmed.com) is a 24-item, low back pain, functional scale recommended for use in low back pain research. 11 Its yes/no format is amenable to telephone follow-up. Higher scores signify greater low back-related functional impairment. The baseline questions referred to the period immediately before ED presentation ("Before you came to the ER today, were you able to."), whereas the 1-week and 3-month follow-up questions referred to the 24 hours preceding the follow-up telephone calls.
Study participants described their back pain with the descriptors "severe," "moderate," "mild," or "none" on an ordinal pain scale. Although not validated, this measure has been used frequently in ED-based low back pain studies. [2] [3] [4] 12 Study participants were asked to answer the question, "Did you require any medication to treat your low back pain?" Study participants were asked to describe the frequency of their low back pain, using the descriptors "always," "usually," "sometimes," "rarely," or "not at all." Low back pain symptomatology is quite variable. Some patients experience no pain unless they move a certain way. Others experience a constant low level of pain. This question helps determine the symptomatic burden of the low back pain in the patient's daily life.
Satisfaction was measured by response to this question: "The next time you go to the ED with low back pain, do you want to receive the same combination of medications?" This question, often used in ED-based acute pain research, allows patients to weigh for themselves the relative efficacy versus tolerability of the investigational medications.
Outcome Measures
The primary outcome was improvement in the RMDQ score between ED discharge and 1-week follow-up. The following secondary outcomes were assessed 1 week after ED discharge: severity of low back pain during the previous 24 hours, the frequency of low back pain during the previous 24 hours, requirement of medication for low back pain during the previous 24 hours, satisfaction with treatment, numbers of days until able to return to usual activities, frequency of follow-up visits to health care providers, and frequency of new symptoms attributable to the investigational medications. Adverse medication effects were elicited with an open-ended question. All study participants were also asked about 3 specific adverse medication effects: drowsiness, dizziness, and stomach irritation. Study participants were asked to rate the severity of these latter 3 symptoms as none, a little, or a lot.
The following secondary outcomes were assessed 3 months after ED discharge: score on the RMDQ, and severity of low back pain during the previous week, using the 4-item ordinal scale described above.
The research associates, who were blinded to assignment, collected all of the data, using structured interviews.
Primary Data Analysis
An intention-to-treat analysis was performed in which all randomized patients with available follow-up data were included regardless of whether they actually used the investigational medication. The primary outcome was a comparison of the change in RMDQ score between baseline and 1 week. Results are reported as means with 95% confidence interval (CI). Between-group differences are reported with 95% CI. Dichotomous outcomes are reported as n/N (%). Between-group differences (absolute risk reduction) are reported with 95% CI. Continuous outcomes are reported as means with SD or medians with interquartile range. We performed a subgroup analysis of the primary outcomes among patients who used the investigational medication at least twice. SPSS (version 21; SPSS Inc, Chicago, IL) was used for all analyses.
We based our sample size calculation assumptions on a recently completed low back pain clinical trial 3 and a widely accepted minimum clinically important improvement of 5 points on the RMDQ. 13 Using a standard a of .05 and a b of .20, we determined the need for 50 subjects in each arm. To account for protocol violations and patients lost to follow-up, and to ensure sufficient power for the intention-to-treat analysis (in previous work, up to one third of enrolled patients did not use the investigational medication), we enrolled 80 patients in each arm.
RESULTS
Characteristics of Study Subjects
During the accrual period, 1,473 patients with low back pain were approached for participation and 240 eligible Patients who responded to either question "more than half the days" or "nearly every day" were considered to screen positive for depression.
patients were randomized (Figure 1 ). Baseline characteristics were comparable between the groups (Table 1) .
Main Results
One week after the ED visit, patients randomized to placebo improved by a mean of 10.9 RMDQ points (95% CI 8.9 to 12.9), whereas orphenadrine patients improved by 9.4 (95% CI 7.4 to 11.5) and methocarbamol patients improved by 8.1 (95% CI 6.1 to 10.1) (Figure 2) . The difference between orphenadrine and placebo was 1.5 RMDQ points (95% CI -1.4 to 4.3), whereas the difference between placebo and methocarbamol was 2.8 (95% CI 0 to 5.7). Secondary outcomes were similar among the groups ( Table 2) .
A majority of patients used naproxen at least once per day ( Table 3) . Use of the investigational medication was slightly less robust. We examined outcomes among participants who used the investigational medication "sometimes," "daily," or "several times daily." In this subgroup analysis, placebo patients reported 1-week RMDQ improvement of 11.3 points (95% CI 9.2 to 13.5), orphenadrine 9.1 points (95% CI 6.8 to 11.4), and methocarbamol 8.2 points (95% CI 5.9 to 10.6).
More than 80% of study participants did not visit another health care provider within 1 week of ED discharge (Table 3) . Among those who did visit one, participants reported follow-up visits to primary care, repeated ED visit, and complementary or alternative practitioners.
Adverse events were relatively uncommon and comparable among the groups (Table E1 , available online at http://www.annemergmed.com). Other than the symptoms reported in Table 4 , only nausea was reported by more than 2 participants. Nausea was reported by 3 methocarbamol patients and 1 placebo patient. There were no serious or unexpected adverse events.
By 3 months after the ED visit, most patients had recovered completely, although one quarter of the sample reported RMDQ scores greater than 8, indicating substantial functional impairment (Tables E2 and E3 , available online at http://www.annemergmed.com). There were no differences in 3-month pain or functional outcomes among the groups.
LIMITATIONS
Our work has a number of limitations (Table E4 , available online at http://www.annemergmed.com). First, this was a study of effectiveness rather than efficacy, meaning that we tested the utility of the investigational medications in a real-world scenario. It is possible that orphenadrine and methocarbamol would have alleviated back pain if study participants were mandated to receive these medications on a regular schedule for several days. Second, studies of this type are susceptible to selection bias. Some of the bias we know about: because patients with chronic low back pain were excluded, the results of this study are not applicable to those with chronic low back pain. However, we do not know whether potentially eligible patients who were screened were different from potentially eligible patients who were missed. Similarly, we do not know whether the 52 patients who refused to participate were different from those who were enrolled. Third, the measurement instruments we used for secondary outcome assessment have not been validated. Therefore, we do not know whether they truly captured the patients' experience. Fourth, we conducted this study in one urban health care system serving a socioeconomically depressed population. Because back pain outcomes may be associated with socioeconomic variables, our results can be generalized most appropriately to EDs that serve similar disadvantaged patient populations.
DISCUSSION
In this randomized, double-blind, comparative effectiveness study, adding skeletal muscle relaxants to naproxen did not improve functional and pain outcomes among patients with acute, nontraumatic, nonradicular low back pain. Many of these patients with acute low back pain had improved by the 1-week follow-up, although more than one third reported persistent moderate or severe low back pain. At 3 months, 45% of our cohort reported low back-related functional impairment. Orphenadrine and methocarbamol are used in more than 250,000 US ED visits for low back pain annually. Among patients with acute low back pain or muscle spasm, monotherapy with methocarbamol has been shown to be superior to placebo in regard to both pain and functionality (Table E5 , available online at http://www.annemergmed. com). 10, 14 We are not aware of other randomized studies in which methocarbamol has been combined with a nonsteroidal anti-inflammatory drug. Orphenadrine has demonstrated superiority to placebo among patients with acute low back pain, although it was not superior to monotherapy with aspirin (Table E6 , available online at http://www.annemergmed.com). [15] [16] [17] [18] We are not aware of other low back pain studies in which orphenadrine was combined with a nonsteroidal anti-inflammatory drug.
Overall, 1-week and 3-month outcomes in this study revealed that most patients experience normalization of low back pain-related functional impairment, although a subset of patients continue to experience both pain and functional impairment. Ideally, patients at higher risk of poor outcome should be targeted for close follow-up, with the goal of preventing the transition from acute to chronic pain. However, it remains difficult to predict which ED patients with acute low back pain are at risk of poor outcomes. 19 Our data contribute to a growing body of literature suggesting that, in general, combinations of medications do not improve low back pain. We have demonstrated previously that adding cyclobenzaprine, oxycodone and acetaminophen, diazepam, or corticosteroids 12 to naproxen is unlikely to benefit the patient presenting with acute low back pain. 3, 4 It is also true that acetaminophen is of no benefit for patients with nonradicular low back pain. 14 Complementary therapies, including acupuncture, 20 yoga, 21 and massage 22 may be offered but have been inadequately studied to determine efficacy in an acute low back pain population. Spinal manipulation is unlikely to benefit ED patients with acute low back pain who are given a prescription for an analgesic medication. 23 Physical therapy too is unlikely to benefit patients in an acute time frame. 23 Emergency physicians should counsel their patients that passage of time will bring improvement and eventual relief to most individuals.
Participation in this study did not commence until an individual was ready for discharge from the ED. Therefore, we do not know whether these skeletal muscle relaxants, when administered acutely in the ED, increase the likelihood of discharge among patients who arrive with marked functional impairment due to low back pain. Also, we excluded from participation patients with chronic or frequent episodic low back pain. Therefore, the role of these medications for these patients is unknown.
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